The impurity is known as N-nitrosodiethylamine, classified as a probable human carcinogen.
The 22 batches were supplied to ScieGen Pharmaceuticals for manufacturing finished Irbesartan tablets in the U.S.
The affected lots, manufactured by ScieGen, have been labeled as Westminster Pharmaceuticals and Golden State Medical Supply. The 75-milligram, 150-milligram and 300-milligram tablets are part of the recall.
More articles on pharmacy:
Pfizer may sell its $2B women’s health unit
CVS pilots membership program to take on Amazon
Regional hospitals want in on lucrative drug trials
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.